Seeking Alpha

Biopharmaceutical researcher Vical (VICL +7%) says it will get a $130M upfront payment from...

Biopharmaceutical researcher Vical (VICL +7%) says it will get a $130M upfront payment from Japan's Astellas Pharma (ALPMY.PK) in a new licensing deal to develop and sell its TransVax vaccine.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|